Bladder Cancer | Unmet Need | US/EU | UNNEON0011-2017
Treatment of unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still the mainstay of treatment. However, following the 2016-2017 FDA approvals of the PD-L1 inhibitor Tecentriq (Roche/Genentech) and the PD-1 inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.
Questions Answered:
What are the treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
What attributes are key influences, which have limited impact, and which are hidden opportunities?
How do current therapies perform on key treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?
What are the prevailing areas of unmet need and opportunity in unresectable locally advanced or metastatic bladder cancer?
What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for unresectable locally advanced or metastatic bladder cancer?
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017
Key companies: Bristol-Myers Squibb, Eli Lilly, Roche/Genentech